Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

Kewaunee Scientific Corporation (“Kewaunee” or the “Company”) announced results for its fourth quarter and its fiscal year ended April 30, 2023.

Fiscal Year 2023 Fourth Quarter Results

Sales during the fourth quarter of fiscal year 2023 were $53,986,000, an increase of 8.6% compared to sales of $49,715,000 from the prior year’s fourth quarter. The increase was a result of higher international segment sales when compared to the prior period due to the continued delivery of several large projects awarded over the course of the past eighteen months.

Pre-tax earnings for the quarter were $2,322,000 compared to $2,345,000 for the prior year period. Net earnings for the quarter were $1,005,000 compared to a net loss of $362,000 for the prior year. EBITDA¹ for the quarter was $3,307,000 compared to $2,969,000 for the prior year period. Diluted earnings per share were $0.34, as compared to a diluted loss per share of $0.13 in the prior year’s fourth quarter.

Domestic Segment

Domestic sales for the quarter were $35,123,000, a decrease of 6.9% from sales of $37,720,000 in the prior year period. Net earnings for the domestic segment were $2,402,000 compared to $2,380,000 in the prior year period. Domestic segment EBITDA was $2,991,000 compared to $2,957,000 for the prior year period. During the fourth quarter, the Company fulfilled most of the outstanding performance obligations for the remaining direct orders in its order backlog, the majority of which were priced and executed prior to the broad-based inflation experienced during the previous fiscal year.

International Segment

International sales for the quarter were $18,863,000, an increase of 57.3% from sales of $11,995,000 in the prior year period. This increase in sales was due to the continued delivery of several large projects awarded over the course of the past eighteen months. Net income for the international segment was $1,106,000 compared to $1,020,000 in the prior year period. International segment EBITDA was $1,546,000 compared to $1,456,000 for the prior year period. EBITDA for the quarter was reduced by $293,000, when compared to the previous year period due to a change in the Corporate cost allocation methodology after completing a revised transfer pricing study.

Corporate Segment

Corporate segment net loss was $2,503,000 for the quarter, as compared to $3,762,000 in the prior year period. Corporate segment EBITDA loss for the quarter was $1,230,000, a favorable improvement of 14.8% from corporate segment EBITDA loss of $1,444,000 for the prior year period. The improved EBITDA was driven by the Corporate cost allocation methodology change discussed above, partially offset by higher pension-related expenses.

The Company’s order backlog was $147.9 million on April 30, 2023, decreasing from $153.2 million on January 31, 2023 and $173.9 million on April 30, 2022. This change in backlog is principally driven by the substantial completion of the previously announced Dangote Oil project in Lagos, Nigeria during the fiscal year and a reduction in market demand within the ASEAN marketplace. The Company’s order backlog for the United States and Indian markets finished the year similar to prior year levels as order rates in these markets remain strong.

“Kewaunee delivered one of the best quarters in the Company’s history as our Associates finished fiscal year 2023 on a high note,” said Thomas D. Hull III, Kewaunee’s President, and Chief Executive Officer. “Profitability improved throughout the year as our teams continued to operate the business with excellence.”

“Our domestic team remained focused on supporting our dealer and distribution partners, concluding a year of significant transition. We have materially completed our remaining performance obligations for the previously discussed direct projects, which were priced and awarded prior to the broad-based inflation experienced during the prior fiscal year. We continue to encourage and support our dealer and distribution partners’ investment in their organizations so they can better serve their respective territories and we can grow our businesses together. We ended the year well positioned with a strong go-to-market strategy, a healthy order backlog, and a robust opportunity pipeline.”

“Our international team has been awarded several large, high-profile projects over the past two years. The fourth quarter of fiscal year 2023 was very strong. This resulted in a significant increase in sales when compared to the prior year quarter. The international team wrapped up what was a record year for both sales and earnings for the segment during the fourth quarter. I could not be prouder of how the team performed during the year.”

Fiscal Year 2023 Full Year Results

Sales during fiscal year 2023 were $219,494,000, an increase of 30.0% compared to sales of $168,872,000 from the prior year. Pre-tax earnings for the fiscal year were $4,498,000 compared to a pre-tax loss of $2,485,000 for the prior year. Net earnings for the fiscal year were $738,000, compared to a net loss of $6,126,000 for the prior year. EBITDA for the fiscal year was $7,517,000 compared to $394,000 for the prior fiscal year. Diluted earnings per share was $0.25, as compared to a loss per share of $2.20 in the prior fiscal year.

Domestic Segment

Domestic sales for the fiscal year were $146,716,000, an increase of 15.7% from sales of $126,848,000 in the prior year. This increase was primarily driven by the pricing of new orders in response to higher raw material input costs. Domestic segment net earnings were $3,408,000 compared to a net loss of $229,000 in the prior fiscal year. Domestic segment EBITDA was $5,802,000 compared to $2,223,000 for the prior year. Domestic segment profitability was negatively impacted during the year by the completion of direct contracts which were priced and awarded prior to the broad-based inflation experienced in the prior fiscal year. Many of these direct contracts were delivered at a loss for the Company.

International Segment

International sales for the fiscal year were $72,778,000, an increase of 73.2% from sales of $42,024,000 in the prior year. The increase in sales was driven by the delivery of several large projects throughout the fiscal year in India, Asia, and Africa. International segment net earnings were $4,511,000 compared to $2,333,000 in the prior fiscal year. International segment EBITDA was $6,650,000 compared to $3,571,000 for the prior year.

Corporate Segment

Corporate segment net loss was $7,181,000 for the fiscal year, as compared to $8,230,000 in the prior fiscal year. Corporate segment EBITDA loss for the fiscal year was $4,935,000, a favorable improvement of 8.6% from corporate segment EBITDA loss of $5,400,000 for the prior year. The favorable change in EBITDA was primarily driven by increased Corporate allocations of $1,172,000 when compared to the prior year due to the change in transfer pricing methodology discussed above, partially offset by higher pension-related expenses and higher operating expenses.

Total cash on hand on April 30, 2023 was $13,815,000, compared to $6,894,000 on April 30, 2022. Working capital was $47,867,000, compared to $49,272,000 on April 30, 2022. Short-term debt was $3,587,000 on April 30, 2023, compared to $1,588,000 on April 30, 2022, and long-term debt was $29,007,000 on April 30, 2023 compared to $29,704,000 on April 30, 2022. The Company’s debt-to-equity ratio on April 30, 2023 was 1.08-to-1, compared to 1.07-to-1 on April 30, 2022.

“Our vision for Kewaunee is to be the global supplier of choice with customers in the laboratory furniture and infrastructure markets,” said Thomas D. Hull III, Kewaunee’s President, and Chief Executive Officer. “In pursuing this vision, we continue to follow the principles that guide our actions:

• We will be easy to do business with;
• We will get closer to our customers;
• We will do everything with the highest quality; and
• We will lead and not follow (we are innovators).”

“Fiscal year 2023 was a transition year for Kewaunee as we emerged from an extremely disruptive period over the past three years dealing with a global pandemic, rapid broad-based inflation, labor shortages and supply chain disruptions. A testament to the character and drive of Kewaunee’s leadership team and Associates is that, while managing through these challenges, we continued to invest in and evolve our business. The benefits of these decisions began to appear as we moved through the year and our financial performance steadily improved. Kewaunee ends fiscal year 2023 with a strong global management team, a healthy backlog, improved manufacturing capabilities, and end-use markets which continue to prioritize investment in projects that require the products Kewaunee designs and manufactures.”

“Moving forward, Kewaunee will continue to invest in developing world class manufacturing capabilities to support our dealer and distribution partners in growing our businesses together. This investment in our capabilities better positions Kewaunee to be the brand of choice. Kewaunee’s future is bright, and I am excited to continue building on our momentum in fiscal 2024.”

To view the full fourth quarter results, click here.

About Kewaunee Scientific

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company’s products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company’s corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific’s website is located at http://www.kewaunee.com.

Contact:

Donald T. Gardner III – Media Contact – (704) 871-3274

Source: Kewaunee Scientific Corporation